Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delavirdine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | MDH1 | P40925 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 14/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delavirdine SCHEMBL29602259 | 1.00 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL30803764 | 1.00 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29714124 | 1.00 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29585604 | 0.99 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL28170537 | 0.99 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL3221265 | 0.99 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL40522 | 0.99 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29746247 | 0.98 | ADRA2A (0.97) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL30703160 | 0.98 | ADRA2A (0.97) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL6390522 | 0.91 | ADRA2A (0.82) | ADRA2AADORA3CHRM1MAOATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 27836 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| US-5691372-A | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-11-25 | — | — | US | claimed |
| EP-0799309-A1 | RIBOZYMES TARGETING THE RETROVIRAL PACKAGING SEQUENCE EXPRESSION CONSTRUCTS AND RECOMBINANT RETROVIRUSES CONTAINING SUCH CONSTRUCTS | GENE SHEARS PTY. LTD. (AU) | 1997-10-08 | — | — | EP | claimed |
| WO-1997026880-A2 | USE OF A COMBINATION OF DELAVIRDINE AND ONE OR MORE PROTEASE INHIBITORS IN HIV-1 INFECTED PATIENTS | PHARMACIA & UPJOHN COMPANY (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997027180-A1 | ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-07-31 | — | — | WO | claimed |
| CN-1146201-A | Sulphonamide derivatives as aspartyl protease inhibitors | VERTEX PHARMA (US) | 1997-03-26 | — | — | CN | claimed |
| EP-0749421-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 1996-12-27 | — | — | EP | claimed |
| WO-1996033187-A1 | OXYGENATED-HETEROCYCLE CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1996-10-24 | — | — | WO | claimed |
| WO-1996033184-A1 | THF-CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1996-10-24 | — | — | WO | claimed |
| WO-1996022368-A1 | RIBOZYMES TARGETING THE RETROVIRAL PACKAGING SEQUENCE EXPRESSION CONSTRUCTS AND RECOMBINANT RETROVIRUSES CONTAINING SUCH CONSTRUCTS | GENE SHEARS PTY. LTD. (AU) | 1996-07-25 | — | — | WO | claimed |
| WO-1995024385-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-09-14 | — | — | WO | claimed |